The Potential of CAR-Modified T Cells in Hematologic Cancers

November 13, 2013
Renier J. Brentjens, MD, PhD

Renier J. Brentjens, MD, PhD, discusses the potential of using CAR-modified T cells to treat hematologic cancers.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the potential of using CAR-modified T cells to treat hematologic cancers.

Clinical Pearls

  • If utilized in the proper context, CAR-modified T cells have a role in the treatment of CLL
  • CAR-modified T cells have the potential to become the standard of care for the treatment of relapsed B-cell acute lymphoblastic leukemia (ALL)
  • Researchers are still learning how to optimize the best way of infusing the cells to get the best response rates
  • Pharmaceutical companies are starting to gain interest in cellular therapies because of its potential to treat B-cell cancers as well as other types of cancer